| European Medicines Agency - Eligible Group Status - COMP [Committee for Orphan Medicinal Products] - SAWP [Scientific Advice Working Party]. | 呼吸系統
> 肺纖維化 | 監管合作夥伴關係
> 與監管機構合作 | Not specified | International | Rarely | 119039359117 |
| When new drugs are approved by the EU medicines agency, we work to represent patient interest with the health service and government agency responsible for approving the drug in Ireland and regulating pricing of new drugs. | 呼吸系統
> 間質性肺病（ILDs） | 監管合作夥伴關係
> 與監管機構合作 | 5,000 | National | Sometimes | 119044171823 |
| Submission on Lutathera for reimbursement decision. | 癌症
> 癌症：神經內分泌腫瘤（NET） | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | National | Rarely | 119039308095 |
| We share the patient experience of living with a condition as part of the reimbursement process. | 神經肌肉
> 神經肌肉疾病：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | National | Sometimes | 119047368493 |
| We submitted our support to the NCPE [National Centre for Pharmacoeconomics] for their appraisal of Lutathera [used to treat adults with certain unresectable or metastatic gastroenteropancreatic neuroendocrine tumors]. | 癌症
> 癌症：神經內分泌腫瘤（NET） | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100 | National | Rarely | 119051190597 |
| Drugs for ataxia are very rare, so we only make submissions as they become available. | 神經退行性
> 共濟失調 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | 1,000 | National | Rarely | 119020208311 |
| European Medicines Agency - Eligible Group Status - COMP [Committee for Orphan Medicinal Products] - SAWP [Scientific Advice Working Party]. | 呼吸系統
> 肺纖維化 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | Not specified | International | Rarely | 119039359117 |
| Meetings with Government Representatives and Department of Health regarding the availability of certain DMTs [Disease-Modifying Therapies primarily used for multiple sclerosis and various autoimmune conditions (like rheumatoid arthritis)]. | 神經系統
> 多發性硬化症 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Regularly | 119074666617 |
| National organization is affiliated with European groups which attempt to have influence. | 一般健康
> 健康素養 | 監管合作夥伴關係
> 與其他醫療倡導者 | 100 | National | Rarely | 119052876993 |
| Advocacy/public affairs messaging about improving reimbursement decision-making for drugs in Ireland. | 癌症
> 癌症：大多數類型 | 影響政策及立法
> 影響醫療保健政策及立法 | 10,000 | National | Rarely | 119063937918 |
| We have advocated for our members to our government representatives at yearly events where we have been invited to government buildings to present to an invited group. | 患者倡議
> 健康活動人士 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 5,000 | National | Rarely | 119047297038 |
| We have advocated for our members to our government representatives at yearly events where we have been invited to government buildings to present to an invited group. | 患者倡議
> 健康活動人士 | 影響政策及立法
> 動員議員及政治領袖 | 5,000 | National | Rarely | 119047297038 |
| We advocate for the most efficient medicine to be available and reimbursed for heart failure patients. | 心臟
> 心臟衰竭 | 影響政策及立法
> 處理醫療護理中的障礙/異常情況 | 5,000 | National | Sometimes | 119051411038 |
| When new drugs are approved by the EU medicines agency, we work to represent patient interest with the health service and government agency responsible for approving the drug in Ireland and regulating pricing of new drugs. | 呼吸系統
> 間質性肺病（ILDs） | 定價及可負擔性倡議
> 參與價格審查委員會談判 | 5,000 | National | Sometimes | 119044171823 |
| Advocacy/public affairs messaging about improving reimbursement decision-making for drugs in Ireland. | 癌症
> 癌症：大多數類型 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 10,000 | National | Rarely | 119063937918 |
| Equity of access: Public patients can wait a lot longer for access to meds approved by EMA [European Medicines Agency], versus private patients whose insurance companies reimburse. | 患者倡議
> 健康活動人士 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | National | Sometimes | 119044976833 |
| We advocate for the most efficient medicine to be available and reimbursed for heart failure patients. | 心臟
> 心臟衰竭 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 5,000 | National | Sometimes | 119051411038 |
| Meetings with Government Representatives and Department of Health regarding the availability of certain DMTs [Disease-Modifying Therapies primarily used for multiple sclerosis and various autoimmune conditions (like rheumatoid arthritis)]. | 神經系統
> 多發性硬化症 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 10,000 | National | Regularly | 119074666617 |
| Equity of access: Public patients can wait a lot longer for access to meds approved by EMA [European Medicines Agency], versus private patients whose insurance companies reimburse. | 患者倡議
> 健康活動人士 | 改善存取途徑
> 解決在獲取和管理方面的差距 | 1,000 | National | Sometimes | 119044976833 |
| Drugs for ataxia are very rare, so we only make submissions as they become available. | 神經退行性
> 共濟失調 | 改善存取途徑
> 改善罕見/極罕見療法的獲取途徑 | 1,000 | National | Rarely | 119020208311 |
| During the course of projects based on issues experienced by the community. | 腸胃
> IBD | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | 5,000 | National | Sometimes | 119020296590 |
| We share the patient experience of living with a condition as part of the reimbursement process. | 神經肌肉
> 神經肌肉疾病：大多數類型 | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | 1,000 | National | Sometimes | 119047368493 |
互動
行動與倡議
9 提及
